Hercules Capital에 대한 매도 수량은 투자자에게 Hercules Capital의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Hercules Capital (NYSE:HTGC) 주식, 공매도 수량 보고

Hercules Capital

Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.

Hercules Capital Inc

<p>Keefe, Bruyette &amp; Woods  analyst Paul Johnson   upgrades Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) from Market Perform to Outperform and raises the price target from $19.5 to $21.5.</p>


News

Upgrades

Price Target

Analyst Ratings

HTGC

Keefe, Bruyette & Woods Upgrades Hercules Capital to Outperform, Raises Price Target to $21.5

<p>JMP Securities  analyst Brian McKenna   reiterates Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Market Outperform and maintains $22 price target.</p>


Reiteration

JMP Securities Reiterates Market Outperform on Hercules Capital, Maintains $22 Price Target

<p>Looking into the current session, <strong>Hercules Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>)</strong> shares are trading at $18.86, after a <strong>0.37%</strong> decrease. Over the past month, the stock fell by <strong>5.80%</strong>, but over the past year, it actually went up by <strong>21.09%</strong>. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1732631415_0.png" alt="Past Year Chart" /></p>

<h3>How Does Hercules Capital P/E Compare to Other Companies?</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Hercules Capital has a lower P/E than the aggregate P/E of <strong>24.2</strong> of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1732631415_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Markets

Price Over Earnings Overview: Hercules Capital

IRON

Disc Medicine Secures $200M Non-Dilutive Loan From Hercules Capital; $30M Drawn At Close With Additional $80M Available Through 2026 To Support Development Of Hematologic Disease Treatments

<p>Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) reported quarterly earnings of $0.51 per share which met the analyst consensus estimate.  The company reported quarterly sales of $125.248 million which beat the analyst consensus estimate of $124.040 million by 0.97 percent.  This is a 7.28 percent increase over sales of $116.744 million the same period last year.</p>


Earnings

Earnings Beats

Hercules Capital Q3 2024 GAAP EPS $0.51, Inline, Sales $125.248M Beat $124.040M Estimate

<p>Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Hercules Capital will report an <strong>earnings per share</strong> (EPS) of $0.51.</p>
<p>The market awaits Hercules Capital's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 11.73% drop in the share price on the following day.</p>
<p>Here's a look at Hercules Capital's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.5</td>
<td>0.50</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.51</td>
<td>0.5</td>
<td>0.56</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-12.0%</td>
<td>1.0%</td>
<td>5.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730217738_0.png" alt="eps graph" /></p>
<h3>Hercules Capital Share Price Analysis</h3>
<p>Shares of Hercules Capital were trading at $20.14 as of October 28. Over the last 52-week period, shares are up 26.23%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Hercules Capital</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Hercules Capital.</p>
<p>Hercules Capital has received a total of 2 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $21.75, the consensus suggests a potential 7.99% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Artisan Partners Asset, Victory Capital Holdings and StepStone Group, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus among analysts is an Sell trajectory for Artisan Partners Asset, with an average 1-year price target of $39.5, indicating a potential 96.13% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Victory Capital Holdings, with an average 1-year price target of $57.64, indicating a potential 186.2% upside.</li>
<li>StepStone Group received a Neutral consensus from analysts, with an average 1-year price target of $58.12, implying a potential 188.58% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Artisan Partners Asset, Victory Capital Holdings and StepStone Group are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federated Hermes</td>
<td>Neutral</td>
<td>1.46%</td>
<td>$271.83M</td>
<td>8.33%</td>
</tr>
<tr>
<td>Artisan Partners Asset</td>
<td>Sell</td>
<td>11.49%</td>
<td>$124.03M</td>
<td>15.76%</td>
</tr>
<tr>
<td>Victory Capital Holdings</td>
<td>Neutral</td>
<td>7.54%</td>
<td>$161.90M</td>
<td>6.75%</td>
</tr>
<tr>
<td>StepStone Group</td>
<td>Neutral</td>
<td>4.71%</td>
<td>$107.34M</td>
<td>3.86%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Hercules Capital ranks in the middle for consensus rating. It ranks at the bottom for revenue growth and gross profit, but at the top for return on equity among its peers.</p>
<h3>Discovering Hercules Capital: A Closer Look</h3>
<p>Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.</p>
<h3>Hercules Capital: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Hercules Capital's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-44.69%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>64.05%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Hercules Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.24%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Hercules Capital's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>1.14%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.95</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/HTGC/earnings"><strong>To track all earnings releases for Hercules Capital visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Hercules Capital's Future Earnings

<p>Wells Fargo  analyst Finian O'Shea   maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $20 to $21.</p>


Wells Fargo Maintains Overweight on Hercules Capital, Raises Price Target to $21

Hercules Capital Announced That Moody's Investors Service Has Reaffirmed Hercules An Investment Grade Credit And Corporate Rating Of Baa3 With A Revised Outlook To Positive, As Well As Its Underlying Analysis

<p><strong>Hercules Capital's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) short percent of float has fallen 3.83% since its last report. The company recently reported that it has <strong>6.00 million shares sold short</strong>, which is 3.77% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 7.36 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Hercules Capital Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723746617_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Hercules Capital has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Hercules Capital's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hercules Capital's peer group average for short interest as a percentage of float is 3.81%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

(HTGC) - Analyzing Hercules Capital's Short Interest

WIIM

ACRE

ALLY

ARES

ATCH

COHN

CRBG

FUTU

HIPO

HOOD

HSBC

IBKR

JFIN

Janus Henderson Group plc Ordinary Shares

KSPI

LPLA

MOGO

MORN

NCPL

NDAQ

NRDS

NTRS

PRAA

RILY

SHF Holdings, Inc. - Class A Common Stock

SHFS

SNEX

SPGI

STEP

TBBK

TROW

VCTR

VOYA

Shares of companies within the broader financial sector are trading lower amid overall weakness following concerns about recently issued US economic data.

Hercules Capital shares are trading lower after the company reported worse-than-expected Q2 revenue results.

<p>Piper Sandler  analyst Crispin Love   maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $22 to $22.5.</p>


Piper Sandler Maintains Overweight on Hercules Capital, Raises Price Target to $22.5

<p>Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) reported quarterly earnings of $0.51 per share which met the analyst consensus estimate. This is a 3.77 percent decrease over earnings of $0.53 per share from the same period last year.  The company reported quarterly sales of $125.006 million which missed the analyst consensus estimate of $127.526 million by 1.98 percent.  This is a 7.55 percent increase over sales of $116.231 million the same period last year.</p>


Earnings Misses

Hercules Capital Q2 2024 GAAP EPS $0.51, Inline, Sales $125.006M Miss $127.526M Estimate

<p>JMP Securities  analyst Devin Ryan   maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Market Outperform and raises the price target from $20 to $22.</p>


JMP Securities Maintains Market Outperform on Hercules Capital, Raises Price Target to $22

<p>Analysts' ratings for Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Hercules Capital, revealing an average target of $20.75, a high estimate of $22.00, and a low estimate of $19.00. Witnessing a positive shift, the current average has risen by 4.64% from the previous average price target of $19.83.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722009619_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Hercules Capital by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hercules Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Hercules Capital's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hercules Capital's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hercules Capital analyst ratings.</strong></a></p>
<h2>All You Need to Know About Hercules Capital</h2>
<p>Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.</p>
<h3>Financial Milestones: Hercules Capital's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Hercules Capital's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-1.53%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>78.6%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Hercules Capital's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.93%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.56%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Hercules Capital's debt-to-equity ratio surpasses industry norms, standing at <strong>0.94</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Hercules Capital Analyst Ratings

<p>Wells Fargo  analyst Finian O'Shea   maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $20 to $22.</p>


Wells Fargo Maintains Overweight on Hercules Capital, Raises Price Target to $22

Hercules Capital Announced That The U.S. Small Business Administration Has Approved Its Fourth Small Business Investment Company Subsidiary, Following The Company's Prior Receipt Of Its "Green Light" Letter To Submit An Application

<p>5 analysts have expressed a variety of opinions on Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $22.00, and a low estimate of $19.00. Observing a 3.54% increase, the current average has risen from the previous average price target of $19.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1720627247_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Hercules Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.50</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hercules Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hercules Capital compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Hercules Capital's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Hercules Capital's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HTGC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hercules Capital analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Hercules Capital</h2>
<p>Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.</p>
<h3>Financial Insights: Hercules Capital</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Hercules Capital's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-1.53%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>78.6%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Hercules Capital's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.93%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hercules Capital's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.56%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Hercules Capital's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.94</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 5 Analyst Recommendations For Hercules Capital

<p>Piper Sandler  analyst Crispin Love   maintains Hercules Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NYSE">HTGC</a>) with a Overweight and raises the price target from $21.5 to $22.</p>


Piper Sandler Maintains Overweight on Hercules Capital, Raises Price Target to $22

Health Care

Financing

General

NEUE

Neuehealth Entered Into A Secured Loan Facility For Up To $150M With Hercules Capital

Hercules Capital renews multi-currency SMBC credit facility

Virtual Meeting to be held on December 12 hosted by JMP Securities. Published first on TheFly – the ultimate source for real-time, market-moving br...

Hercules Capital management to meet virtually with JMP Securities

JMP Securities analyst Brian McKenna maintained a Buy rating on Hercules Capital (HTGC – Research Report) today and set a price target of $22.00. T...

Hercules Capital (HTGC) Receives a Buy from JMP Securities

Hercules Capital: Are The Dividends Safe? I'm Buying!

Invest In $95,000 BDC Portfolio For $10,000 Annual Income And Durable Compounding

PBDC: A Diversified BDC Choice

Keefe Bruyette upgraded Hercules Capital (HTGC) to Outperform from Market Perform with a price target of $21.50, up from $19.50. The firm expects b...

Hercules Capital upgraded to Outperform from Market Perform at Keefe Bruyette

TriplePoint Venture Growth: Is The 15% Dividend Yield Sustainable?

5 BDCs With High Dividend Resistance To Falling Interest Rates

My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys

AAPL

ABBV

AGNC

ALIZF

APLE

ARCC

AVGO

BABA

BASFY

BAYZF

BIZD

BXSL

CBAUF

CION

CSCO

CSWC

FDUS

FSNUF

GAIN

GBDC

GILD

GLAD

GOOD

GSBD

INTC

KBDC

MAIN

MFIC

MSDL

MSFT

NEWT

NVDA

OBDC

OCSL

PBDC

PSEC

RITM

SEMHF

SHEL

STAG

STWD

TCPC

TPVG

TSLX

UNIT

Press Releases

Hercules Capital Announces Upcoming Event for the Financial Community

Hercules Capital Receives Reaffirmed Baa3 Investment Grade Rating with Revised Outlook to Positive from Moody's Investors Service

Hercules Capital Announces Date for Release of Third Quarter 2024 Financial Results and Conference Call

Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the Third Quarter 2024

Hercules Capital Reports Third Quarter 2024 Financial Results

Behavox Secures $70 Million Credit Facility from Hercules Capital for Strategic Expansion

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Hercules Capital Renews and Increases Its Multi-Currency SMBC Credit Facility to $300.0 Million

Insurance

Remodel Health Raises More Than $100 Million to Continue Expansion in ICHRA Market

Comments

Hercules Capital

매도 수량

Hercules Capital (NYSE:HTGC) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌